Notional cash at 31 December was ~US$200m – ample capital to support the launch (mainly labour cost). MSB has ~2 years worth of Ryoncil product in storage. We do not anticipate a further requirement for equity from shareholders. Catalysts include first product sales for Ryoncil and the announcements regarding a probable pathway to accelerated approval for Revascor in heart failure.
BP need to talk to Stocksa because he posts about an upcoming Cap raise.
Yeah,
Aloha.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
0.040(2.23%) |
Mkt cap ! $2.335B | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.89 | $1.83 | $5.854M | 3.157M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 41898 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 2779 | 8 |
View Market Depth
| Last trade - 13.50pm 16/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |